bonyf NV
EEURONEXT:MLBON1.90
EUR
0.00
(0.00%)
ISIN
BE6333353298
Return %
Stock
S&P 500
1Y
-85.27
14.39
3Y
-84.17
81.42
5Y
- -
68.62
Capital Structure
EUR
•
in mil. unless spec.Working Capital
EUR
•
in mil. unless spec.Growth Rates
EUR
•
in mil. unless spec.Quarterly Revenue
EUR
•
in mil. unless spec.Quarterly Earnings Per Share
EUR
•
in mil. unless spec.Quarterly Dividends Per Share
EUR
•
in mil. unless spec.Company Description
- CEO
- Jean-Pierre Bogaert
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Kalvekeetdijk 179 Knokke Heist Belgium 8300
- IPO Date
- Mar 17, 2022
- Website
- bonyf.com
- Similar Companies
- Business
- bonyf N.V. specializes in the research, development, production, and distribution of innovative oral, dental, denture, orthodontic, and wound care products. Its core product portfolio includes oral care solutions such as PerioTabs®, a chlorhexidine-free brushing treatment reducing gingivitis and periodontitis; PerioCream, a mucoadhesive dental treatment certified as a Class IIa medical device under EU Medical Device Regulation; denture cleansing and disinfecting tablets based on its patented NitrAdine® formulation; orthodontic care products; and wound care formulations. The company operates globally, exporting its trusted brands to 36 countries with headquarters in Knokke-Heist, Belgium, and production facilities in Switzerland. Founded in 1979, bonyf has recently expanded through strategic alliances, including a significant partnership with Group Pharmaceuticals Ltd for manufacturing and distribution of NitrAdine® products in India, and a new distribution partnership with Honest Pharma for market entry into the United States. The company also secured EU patent protection and has a pending US patent for its flagship products PerioTabs® and PerioCream, highlighting its ongoing commitment to innovation. It announced the anticipated market launch of PerioCream designed specifically for dental professionals and canceled a previously considered capital increase following positive business developments, reflecting a strong financial position and strategic growth focus. bonyf targets healthcare professionals and consumers seeking advanced oral hygiene and dental treatments, leveraging its proprietary NitrAdine® technology as a foundation for product innovation. The company maintains a robust R&D pipeline aimed at developing new formulations that address infection-induced oral and wound care problems, positioning itself as a specialist in these segments with a premium Swiss quality standard. Its latest efforts emphasize expanding international reach through partnerships, regulatory certifications, and new product launches to enhance market penetration across Europe, Asia, and North America.